CERo Therapeutics Holdings, Inc. (CERO)
Market Cap | 6.53M |
Revenue (ttm) | n/a |
Net Income (ttm) | -2.75M |
Shares Out | 51.35M |
EPS (ttm) | -0.30 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 877,085 |
Open | 0.130 |
Previous Close | 0.130 |
Day's Range | 0.125 - 0.132 |
52-Week Range | 0.122 - 12.800 |
Beta | -0.42 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 14, 2024 |
About CERO
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California. [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/f/o/gen59-2492057-2531284.jpg)
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `
![](https://cdn.snapi.dev/images/v1/4/m/press13-2477570.jpg)
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CER...
![](https://cdn.snapi.dev/images/v1/c/f/press1-2431855.jpg)
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of eng...
![](https://cdn.snapi.dev/images/v1/p/r/press4-2312903.jpg)
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell t...
![](https://cdn.snapi.dev/images/v1/a/a/press3-2276897.jpg)
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination
OAKLAND, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (“PBAX”) and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to adv...
![](https://cdn.snapi.dev/images/v1/3/2/press11-1920522.jpg)
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics
SOUTH SAN FRANCISCO & OAKLAND, Calif.--(BUSINESS WIRE)--CERo Therapeutics, Inc. (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics t...
![](https://cdn.snapi.dev/images/v1/9/c/press3-1665459.jpg)
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement
SEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and ...
![](https://cdn.snapi.dev/images/v1/p/r/press6-1609316.jpg)
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders
SEATTLE, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and ...